Interestingly, in multiple myeloma cells treatment with lenalidomide increased ubiquitination and subsequent degradation of IKZF1 and IKZF3, demonstrating that small molecules can modulate the CUL4-DDB1-DCAF complex. Here, IKZF3 is linked to plasma cell myeloma.